The combined effects of novel tocotrienols and lovastatin on lipid metabolism in chickens

Atherosclerosis

Volumn 156, Issue 1, 2001, Pages 39-47

  Qureshi, Asaf A ^a   Peterson, David M ^b,c  

^a Advanced Medical Research   (United States)

^b U S DAIRY FORAGE RESEARCH CENTER   (United States)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

HMG CoA reductase; Lipid metabolism; Lovastatin; Novel tocotrienols of rice bran

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; BETA TOCOPHEROL; BETA TOCOTRIENOL; CHOLESTEROL; CHOLESTEROL 7ALPHA MONOOXYGENASE; GAMMA TOCOPHEROL; GAMMA TOCOTRIENOL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; MEVINOLIN; THROMBOCYTE FACTOR 4; THROMBOXANE B2; TOCOTRIENOL DERIVATIVE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VITAMIN;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHICKEN; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; LIPID BLOOD LEVEL; LIPID METABOLISM; NONHUMAN; PRIORITY JOURNAL; TRIACYLGLYCEROL BLOOD LEVEL;

ANIMALS; ANTICHOLESTEREMIC AGENTS; CHICKENS; CHOLESTEROL; CHOLESTEROL 7-ALPHA-HYDROXYLASE; DIET; DRUG SYNERGISM; FEMALE; HYDROXYMETHYLGLUTARYL COA REDUCTASES; LIPID METABOLISM; LIPOPROTEINS, LDL; LIVER; LOVASTATIN; VITAMIN E;

EID: 0035004469     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0021-9150(00)00612-2     Document Type: Article

References (39)

1. Qureshi A.A., Bradlow B.A., Salser W.A., Brace L.D. Novel tocotrienols of rice bran modulate cardiovascular disease risk parameters of hypercholesterolemic human. J. Nutr. Biochem. 8:1997;290-298.
2. Qureshi N, Qureshi A.A. Tocotrienols: novel hypocholesterolemic agents with antioxidant properties. Packer L, Fuchs J. Vitamin E in Health and Disease. 1993;247-267 Marcel Dekker, Inc, New York, NY.
3. Hood R.L., Sidhu G.S. Effects guar gum and tocotrienols on cholesterol metabolism on the Japanese quail. Nutr. Res. 12:1992;S117-S127.
4. Khor H.T., Chieng D.Y., Ong K.K. Tocotrienols inhibit HMG-CoA reductase activity in the guinea pig. Nutr. Res. 15:1995;537-544.
5. Watkins T., Lenz P., Gapor A., Struck M., Tomeo A., Bierenbaum M. Tocotrienol as a hypocholesterolemic and antioxidant agent in rats fed atherogenic diets. Lipids. 28:1993;1113-1118.
6. Hood R.L. Tocotrienols and cholesterol metabolism. Ong ASH, Niki E, Packer L. Nutrition, Lipids, Health, and Diseases, 1995;96-103 AOCS Press, Champaign, Illinois.
7. Parker R.A., Pearce B.C., Clark R.W., Gordon D.A., Wright J.J.K. Tocotrienols regulate cholesterol production in mammalian cells by post-transcriptional suppression of 3-hydroxy-3-methylglutaryl coenzyme A reductase. J. Biol. Chem. 268:1993;11230-11238.
8. Goodman G. The Pharmaceutical Basis of Therapeutics. 9th Edition :1996;McGraw Hill, Health Professions Division, New York, USA.
9. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature (London). 343:1990;425-435.
10. Nakanishi M., Goldstein J.L., Brown M.S. Multivalent control of 3-hydroxy-3-methylglutaryl coenzyme A reductase: mevalonate-derived product inhibits translation of mRNA and accelerates degradation of enzyme. J. Biol. Chem. 263:1988;8929-8937.
11. United States of America, Food & Drug Administration. Tocopherols and derivatives. Proposed affirmation of GRAS status for certain tocopherols and removal of certain others from GRAS status as direct human food ingredients. Federal-Register; 43 (209, October 27) 50193-50198, 1978.
12. Allen P.C., Wong H.Y.C. Effect of atherogenic diet on chicken plasma lipids and lipoproteins. Poultry Sci. 72:1993;1673-1678.
13. Wong H.Y.C., Loo G., Sherief H.T., Zhuang H. Effects of diazepam (valium) on aortic atherogenesis and plasma lecithin: cholesterol acyltransferase activity in cockerels fed an atherogenic diet. Artery. 19:1992;39-46.
14. Leveille G.A., Romsos D.R., Yeh Y.Y., O'Hea E.K. Lipid biosynthesis in the chick: a consideration of site of synthesis, influence of diet and possible regulatory mechanisms. Poultry Sci. 54:1975;1075-1093.
15. Shrago E., Glennon J.A., Gordon E.S. Comparative aspects of lipogenesis in mammalian tissues. Metabolism. 20:1971;54-62.
16. Qureshi AA, Lane RH, Salser AW. Tocotrienols and tocotrienol-like compounds and method for their use, US Patent. 5 919 818. July 6, 1999.
17. Qureshi A.A., Abuirmeileh N., Burger W.C., Din Z.Z., Elson C.E. Effect of AMO 1618 on cholesterol and fatty acid metabolism in chickens and rats. Atherosclerosis. 46:1983;203-216.
18. Abacus Concepts, StatView. Abacus Concepts, Inc., Berkeley, CA, 1992.
19. Huang W.Y., Kummerow F.A. Cholesterol and fatty acid synthesis in swine. Lipids. 11:1976;34-41.
20. Qureshi A.A., Bradlow B.A., Brace L., Manganello J., Peterson D.M., Pearce B.C., Wright J.J.K., Gapor A., Elson C.E. Response of hypercholesterolemic subjects to administration of tocotrienols. Lipids. 30:1995;1171-1177.
21. Qureshi A.A., Pearce B.C., Nor R.M., Gapor A., Peterson D.M., Elson C.E. Dietary α-tocopherol attenuates the impact of γ-tocotrienol on hepatic 3-hydroxy-3-methylglutaryl coenzymeA reductase activity in chickens. J. Nutr. 126:1996;389-394.
22. Khor, H.T, Ng, T.T. Effects of administration of α-tocopherol and tocotrienols on serum lipid and liver HMG-CoA reductase activity, Proc. PORIM Int. Palm Oil Congress (Nutrition). 1999, 1-6 Febuary, 177-186.
23. Panini S.R., Delate T.A., Sinensky M. Post-transcriptional regulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase by 24 (S), 25-oxidolanosterol. J. Biol. Chem. 267:1992;12644-12654.
24. Brown M.S., Goldstein J.L. A receptor mediated pathway for cholesterol homeostasis. Science. 232:1986;34-47.
25. Illingworth D.R. Lipid-lowering drugs: an overwiew of inductions and optimum therapeutic use. Drug. 33:1987;259-279.
26. Bilheimer D.W., Grundy S.M., Brown M.S., Goldstein J.L. Mevinolin and colestipol stimulate receptor mediatorial clearance of LDL from plasma in familial hypercholesterolemia heterozygotes. Proc. Natl. Acad. Sci. (USA). 80:1983;4124-4128.
27. Grundy S.M., Vega C.L. Influence of mevinolin on metabolism of LDL in primary moderate hypercholesterolemia. J. Lipid. Res. 26:1985;1464-1475.
28. Ilingworth D.R. Drug therapy of hypercholesterolemia. Clin. Chem. 34:1988;B123-B132.
29. Steiner M, Glantz M. Vitamin E plus aspirin compared with aspirin in patients with transient ischemic attacks. Am. J. Clin. Nutr. 62:(Suppl 6):1995;1381S-1384S.
30. 2, and platelet factor 4 in pigs with inherited hyperlipidemias. Am. J. Clin. Nutr. 53:1991;1042S-1046S.
31. Qureshi A.A., Qureshi N., Wright J.J.K., Shen Z., Kramer G., Gapor A., Chong Y.H., DeWitt G., Ong A.S.H., Peterson D.M., Bradlow B.A. Lowering of serum cholesterol in hypercholeterolemic humans by tocotrienols (Palmvitee). Am. J. Clin. Nutr. 53:1991;1021S-1026S.
32. Naito N.K. The clinical significance of apolipoprotein measurements. J. Clin. Immunoassay. 9:1986;11-20.
33. Theriault A., Wang Q., Gapor A., Adeli K. Effects of gamma-tocotrienols on apo B synthesis, degradation, and secretion in HepG2 cells. Arterioscler. Thromb. Vasc. Biol. 19:1999;704-712.
34. Kleinsek D.A., Jabalquinto A.M., Porter J.W. In vivo and in vitro mechanisms regulating rat liver β-hydroxy-β-methylglutaryl coenzymeA reductase activity. J. Biol. Chem. 255:1980;3918-3923.
35. Chang M.W., Johnson M.A. Effect of garlic on carbohydrate metabolism and lipid synthesis in rats. J. Nutr. 110:1980;931-936.
36. Brown G., Albers J.J., Fisher L.D., Schaefer S.M., Lin J.T., Kaplan C., Zhao X.Q., Bisson B.D., Fitzpatrick V.F., Dodge H.T. Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B. New. Engl. J. Med. 323:1990;1289-1298.
37. Lipids Research Clinics Program. The lipid research clinics coronary primary prevention trial results, reduction in incidence of coronary heart disease. J Am Med Assoc. 1984; 251: 351-364.
38. Frick M.H., Elo O., Haapa K., Heinonen O.P., Heinsalmi P., Helo P., Huttunen J.K., Kaitaniemi P., Koskinen P., Manninen V. Helsinki Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment changes in risk factors and evidence of coronary heart disease. New Engl. J. Med. 317:1987;1237-1245.
39. Carlson L.A., Rosenhamer G. Reduction of mortality in the Stockholm Ischemic Heart Disease, secondary prevention study by combined treatment with clofibrate and nicotinic acid. Acta Med. Scand. 223:1988;405-418.